CVSI - GRAND SLAM - Generational Opportunity - BUY!
CVSI
is a once in a generation opportunity. The company produces pharmaceutical grade CBD from cannabis. There are too many catalysts to name but the most recent one is that they have applied to move off the pink sheets to the NASDAQ. Also, Canada just legalized cannabis for recreational use and I believe the U.S. will be soon to follow. Lastly, CBD has a lot of promise for health and lifestyle products. CBD is literally being put in to make-up to dog treats. I came home the other night and my wife showed me the new dog treats for my aggressive basset hound. The dog treats had CBD as an ingredient and I checked Amazon to see the reviews. The product had 5 star reviews and everyone loved them. Also, CBD is legal from Hemp in the U.S.
BUY BUY BUY!
We are beginning the Cycle 3rd Wave now and are making new highs.
-AB
Comment:
Near-Term Price Target (3 Months): $4
Comment:
Please ignore (CBD) ticker above. The stocks ticker is CVSI.
Comment:
Wave 1 complete
Wave 1 complete
Comment:
$4.00 Target Hit
$4.00 Target Hit
Comment:
Next Target: $5.27
Comment:
Comment:
CVSI is ROCKING!
We have 2 EXTENDED WAVES!!!
It is almost impossible to predict where extended waves end but you can look at price-action and Fibonacci Levels.
We have 2 EXTENDED WAVES!!!
It is almost impossible to predict where extended waves end but you can look at price-action and Fibonacci Levels.
Comment:
Second Quarter 2018 Financial and Operating Highlights
Record Sales of $12,349,000 , an increase of 203% compared to Q2 2017
Record Gross Profit of $9,060,000 , an increase of 219% compared to Q2 2017
Record GAAP Net Income of $3,186,000 , an improvement of $4,178,000 compared to Q2 2017
Record Adjusted EBITDA $3,806,000 , an improvement of $4,087,000 compared to Q2 2017
Increased Retail Channel Distribution to 1,968 Stores as of June 30, 2018 , an 11% sequential increase over the Company’s retail store count for the first quarter of 2018
Continued Progress in Drug Development Division including preclinical progress with CVSI-007, the Company’s patent-pending synthetic-based cannabidiol, which will be co-administered with nicotine to provide treatment options for smokeless tobacco use and addiction, currently a multibillion-dollar market with no currently FDA -approved drugs available to help patients.
Record Sales of $12,349,000 , an increase of 203% compared to Q2 2017
Record Gross Profit of $9,060,000 , an increase of 219% compared to Q2 2017
Record GAAP Net Income of $3,186,000 , an improvement of $4,178,000 compared to Q2 2017
Record Adjusted EBITDA $3,806,000 , an improvement of $4,087,000 compared to Q2 2017
Increased Retail Channel Distribution to 1,968 Stores as of June 30, 2018 , an 11% sequential increase over the Company’s retail store count for the first quarter of 2018
Continued Progress in Drug Development Division including preclinical progress with CVSI-007, the Company’s patent-pending synthetic-based cannabidiol, which will be co-administered with nicotine to provide treatment options for smokeless tobacco use and addiction, currently a multibillion-dollar market with no currently FDA -approved drugs available to help patients.
Comment:
